<DOC>
	<DOCNO>NCT00002429</DOCNO>
	<brief_summary>This study test new form didanosine , ddI EC , coat pill pass stomach dissolve . The purpose study compare effectiveness anti-HIV drug combination include ddI EC versus another anti-HIV drug combination .</brief_summary>
	<brief_title>Evaluation Anti-HIV Drug Combination That Includes Coated Form Didanosine ( ddI EC ) Compared Typical Anti-HIV Drug Regimen</brief_title>
	<detailed_description>Patients randomize 1 2 group 48 week open-label treatment . Group 1 receive ddI EC plus d4T plus NFV . Group 2 receive Combivir plus NFV . Antiviral activity determine proportion patient HIV RNA level less 400 copies/ml Week 48 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have viral load least 2,000 copies/ml CD4 count least 200 cells/mm3 . Are least 18 year old . Agree practice sexual abstinence use effective barrier method birth control ( condom ) . Exclusion Criteria Patients eligible study : Have severe diarrhea within 30 day study entry . Have history pancreatic disease serious condition . Have hepatitis within 30 day study entry . Are diagnose opportunistic ( AIDSrelated ) infection time enrollment . Are unable take medication mouth . Have receive certain medication . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Stavudine</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>